Parasite | Eso | Sto | Cancer | ESD
[DDW 2004 in Chicago]
13³â¸¸¿¡ DDW¿¡ Âü¼®Çß½À´Ï´Ù. Âü ¸¹ÀÌ º¯ÇØÀÖ¾ú½À´Ï´Ù.
2014³â 5¿ù 3ÀÏ Åä¿äÀÏ ¿ÀÀü ¿ì¸®³ª¶ó ³»½Ã°æÇÐȸ¿Í ¹Ì±¹³»½Ã°æÇÐȸÀÇ joint symposiumÀÌ ÀÖ¾ú½À´Ï´Ù. Rex, À̺¸ÀÎ, ½É±â³², ¹®Á¾È£, ÀÌ¿ëÂù ±³¼ö´ÔÀÌ °ÀÇÇϼ̽À´Ï´Ù. ´ë¼ºÈ²À̾ú´Ù°í Çϴµ¥ Àú´Â ½ÃÄ«°í¿¡ ¾îÁ¦ Á¡½É ¹«·Æ µµÂøÇÏ¿© Âü¼®ÇÏÁö ¸øÇß½À´Ï´Ù. ¹«Ã´ ¾Æ½¬¿ü½À´Ï´Ù. Å« ¹Ú¼ö·Î ÃàÇÏÇÕ´Ï´Ù.
2014³â 5¿ù 3ÀÏ Åä¿äÀÏ DDW ±â°£À» ÀÌ¿ëÇÑ separate meetingÀ¸·Î WEO (World Endoscopy Organization)ÀÇ Stomach Subcommittee ¹ÌÆÃÀÌ ÀÖ¾ú½À´Ï´Ù. Àú´Â Gastric Cancer in Korea¶ó´Â Á¦¸ñÀÇ ¹ßÇ¥¸¦ ÇÏ¿´½À´Ï´Ù. ÀϺ»ÀÇ»çµéÀº È®´ë³»½Ã°æ¿¡ ´ëÇÑ ¹ßÇ¥¸¦ Çß½À´Ï´Ù.
2014. 5. 2. ÀÏ¿äÀÏ ASGE/JSGE (¹Ì±¹³»½Ã°æÇÐȸ/ÀϺ»³»½Ã°æÇÐȸ) joint symposium
1) NBI update for lower GI neoplasia - Shinji Tanaka
ÀϺ»¿¡¼ ÃÖ±Ù JNET (Japan NBI Expert Team)°¡ ±¸¼ºµÇ¾î ¸¹Àº ¿¬±¸¿Í Åä·ÐÀÌ ÁøÇàµÇ°í ÀÖ´Â ¸ð¾çÀÔ´Ï´Ù. NICE ºÐ·ù°¡ NBI ¼Ò°ßÀ» ±â¼úÇϴ ǥÁØ ¹æ¹ýÀÌ µÇ¾ú½À´Ï´Ù.
Screening colonoscopy setting ¿¡¼ NBI´Â ¼±Á¾ ¹ß°ßÀ²¿¡ µµ¿òÀÌ µÇÁö ¾Ê´Â´Ù´Â µÎ°³ÀÇ review articleÀÌ ÀÖ¾ú½À´Ï´Ù. New NBI (Lucera Elite)´Â NBI ±â´ÉÀÌ Çâ»óµÇ¾î polyp detection rate°¡ ´õ ÁÁ¾ÆÁ³´Ù´Â multicenter study°¡ 2013³â UEGW¿¡¼ ¹ßÇ¥µÇ¾ú½À´Ï´Ù.
2) Endocytoscopy - Haruhiro Inoue
White light endoscopy, NBI, magnifying, endocytoscopy¸¦ ÇÑ°³ÀÇ scope·Î ÇÒ ¼ö ÀÖ°Ô µÈ ¸ð¾çÀÔ´Ï´Ù. ±¸Ã¼ÀûÀÎ specificationÀº ¼Ò°³µÇÁö ¾Ê¾Ò½À´Ï´Ù. Inoue ¹Ú»ç°¡ OlympusÀÇ ±â¼ú°í¹®ÀÓÀ» °í·ÁÇÏ¸é ¾Æ¸¶ ºñ¹Ð»çÇ×ÀÏÁöµµ ¸ð¸£°Ú½À´Ï´Ù. Á¦ ÁüÀÛÀÏ »ÓÀÌÁö¸¸.
3) Confocal endomicroscopy for upper GI neoplasia - Kakuzi Sugiyama, Jikei University School of Medicine (kaz_sum@jikei.ac.jp)
ÀþÀº ¼±»ýÀ̾ú´Âµ¥ ¿µ¾îµµ ÀßÇÏ°í ½½¶óÀ̵å·Î ¿¹»Ú°í ¹ßÇ¥ ŵµµµ ÁÁ¾Ò½À´Ï´Ù. "I am one of few CLE believers in the far east"¶ó´Â ¸»·Î °á·ÐÀ» ¸Î¾ú½À´Ï´Ù. Believer¶ó´Â ´Ü¾î¿¡ °ÇÑ ´À³¦À» ¹Þ¾Ò½À´Ï´Ù. Believer¶ó... Confocal lase endomicroscopy (CLE)´Â ÀÏ°ß º´¸®¿Í ºñ½ÁÇÏÁö¸¸ °á±¹Àº ³»½Ã°æ°ú Á» ´õ ºñ½ÁÇÑ ´À³¦À̶ó°í ÇÕ´Ï´Ù.
4) Extra-wide-angle-view colonoscopy - Toshio Uraoka
No comment
5) Overview of advanced imaging in US - Michael B. Wallace (Mayo Clinic)
µ¿¾ç°ú ¼¾çÀÇ Â÷ÀÌ, ¼¾ç¿¡¼ÀÇ ÃÖ±Ù º¯È °æÇâ¿¡ ´ëÇÏ¿© Àß Á¤¸®ÇÏ¿´½À´Ï´Ù. ¾Æ½±±âµµ ÇÏ°í ºÎ·´±âµµ ÇÑ °ÍÀº °»ç°¡ ¸¶Áö¸·À» '¾Æ¸®°¡Åä °íÀÚÀ̸¶½º'·Î ¸¶¹«¸®Çß´Ù´Â Á¡ÀÔ´Ï´Ù.
6) Overview and general discussion - »çȸ: Kenneth Wang
¿ì¸®³ª¶ó´Â ´Ù¾çÇÑ ÁÖÁ¦¸¦ Á» ´õ clinicalÇÑ °üÁ¡¿¡¼ ´Ù·ð´Ù¸é, ÀϺ»Àº ÀϺ» ³¿»õ°¡ ¹°¾À ³ÑÄ¡´Â ¿À´ÙÄí(«ª«¿«¯)Àû °ÀÇ·Î ½ÉÆ÷Áö¾öÀ» ±¸¼ºÇÑ °ÍÀÌ Â÷À̶ó¸é Â÷ÀÌ¿´½À´Ï´Ù.
2014³â 5¿ù 5ÀÏ ¿ù¿äÀÏ ¿ÀÀü 10½Ã Surveillance colonoscopy: beyond the basics
¾îÁ¦´Â ¸ô·¡ »çÁøÀ» Âï¾ú½À´Ï´Ù. ±×·±µ¥ ¿À´ÃÀº ÁÂÀåÀÌ »çÁøÂïÁö ¸»¶ó°í °Á¶ÇÏ´Â ¹Ù¶÷¿¡ ÂïÁö ¸øÇß½À´Ï´Ù.
1) Chemoprevention: what should I recommend for my sporadic polyp patient? Dennis J. Ahnen.
¾Æ½ºÇǸ°ÀÌ ¿ëÁ¾°ú ´ëÀå¾ÏÀÇ ¹ß»ý·üÀ» ÁÙÀÔ´Ï´Ù. ƯÈ÷ ±ÙÀ§ºÎ ´ëÀå¾ÏÀ» ÁÙÀÌ´Â È¿°ú°¡ ÀÖ½À´Ï´Ù. ´ëÀå¾Ï ¹ß»ý·üÀº 40%, »ç¸Á·üÀº 20% °¨¼Ò½Ãŵ´Ï´Ù. È¿°ú¸¦ º¸±â À§Çؼ´Â ¾Æ½ºÇǸ°À» 5-10³â Á¤µµ Áö¼ÓÀûÀ¸·Î º¹¿ëÇØ¾ß ÇÕ´Ï´Ù. Risk benefit balanceµµ °í·ÁÇØ¾ß Çϴµ¥¿ä... ¿¹¸¦ µé¾î ÇÕº´Áõ À§ÇèÀº °ú´ëÆò°¡µÇ°í ÀÖ´Ù°í »ý°¢µË´Ï´Ù. ¿Ö³ÄÇϸé ÃâÇ÷ÀÇ Àý¹ÝÀº ¾Æ½ºÇǸ°À» ÁÖÁö ¾Ê¾Æµµ ¹ß»ýÇßÀ» °ÍÀ̱⠶§¹®ÀÔ´Ï´Ù. ½ÉÇ÷°ü°è À§ÇèÀÎÀÚ°¡ ÀÖ´Â »ç¶÷¿¡°Ô´Â ´ç¿¬È÷ ¾Æ½ºÇǸ°ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±×·¸Áö ¾Ê´õ¶óµµ À§Àå°üÃâÇ÷ À§ÇèÀÌ ³·Àº »ç¶÷Àº ¾Æ½ºÇǸ°ÀÇ ÀûÀÀÁõÀÌ µË´Ï´Ù. ÇÑ °¡Áö ÁÖÀÇÇÒ Á¡. Discussion/decision¿¡ ´ëÇÑ ±â·ÏÀ» Àß ³²°Ü¾ß ÇÕ´Ï´Ù. ´ëÀå¾Ï ¿¹¹æÀ» À§ÇÑ ¾Æ½ºÇǸ° º¹¿ë¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀÌ ¾ø±â ¶§¹®ÀÔ´Ï´Ù.
@ ÀÌÁØÇà comment: µ¥ÀÌŸ°¡ ºÎÁ·ÇÏÁö¸¸ ¾Æ½ºÇǸ°ÀÌ ´ëÀå¾ÏÀ» ÁÙÀÌ´Â °ÍÀº È®½ÇÇØ º¸ÀÔ´Ï´Ù. ±×·¯³ª Áß¿äÇÑ µÎ À̽´°¡ ³²¾ÆÀÖ´Ù°í »ý°¢µË´Ï´Ù. (1) ¿ì¸®³ª¶ó¿¡¼´Â GI bleeding rigk°¡ ´õ ³ôÀ¸¹Ç·Î risk benefit ratio°¡ ´Þ¶óÁú ¼ö ÀÖ½À´Ï´Ù. (2) Á¤±âÀûÀÎ ´ëÀå³»½Ã°æ °Ë»ç¸¦ ÇÏ´Â »óȲ¿¡¼µµ ¾Æ½ºÇǸ°ÀÌ È¿°ú°¡ ÀÖ´ÂÁö ¾Ë ¼ö ¾ø½À´Ï´Ù. ¾Æ¸¶ ¾à°£ÀÇ additive effect´Â ÀÖ°ÚÀ¸³ª false sense of safety°¡ ¹®Á¦ÀÔ´Ï´Ù. Floor¿¡¼ "¾Æ½ºÇǸ°À» ¸Ô´Â »ç¶÷Àº ´ëÀå¾Ï¿¡ ¾È °É¸°´Ù´Â Âø°¢ ¶§¹®¿¡ ³»½Ã°æ °Ë»ç¸¦ ¹ÞÁö ¾ÊÀ» À§ÇèÀÌ ÀÖ´Ù"´Â comment°¡ ÀÖ¾ú½À´Ï´Ù. Ÿ´çÇÑ ÁöÀûÀÔ´Ï´Ù.
2) Serrated neoplasia: accurate diagnosis and proper followup - David A. Lieberman
Serrated pathway´Â ´ëÀå¾ÏÀÇ 20%¸¦ Â÷ÁöÇÏ´Â °ÍÀ¸·Î »ý°¢µË´Ï´Ù. º´¸®ÀÇ»ç´Â ºÐ·ù¸¦ À߸øÇÏ°í (misclassification), ³»½Ã°æÀÇ»ç´Â ³õĨ´Ï´Ù (miss). ´ëÀå³»½Ã°æÀǻ翡 µû¶ó¼ proximal polyp ¹ß°ßÀ²ÀÌ 1%¿¡¼ 18%±îÁö Â÷ÀÌ°¡ ³´Ù´Â ¿¬±¸µµ ÀÖ½À´Ï´Ù. Interval cancerÀÇ Æ¯Â¡ÀÌ serrated adenomaÀÇ Æ¯¼º°ú ºñ½ÁÇÏ´Ù´Â Á¡¿¡¼ serrated adenoma°¡ Áß°£¾ÏÀÇ ÀÏºÎ¿Í °ü·ÃµË´Ï´Ù. Serrated adenoma ȯÀÚ¿¡¼ surveillance °£°ÝÀ» ¾à°£ ÁÙÀÌ´Â recommendationÀÌ º¸ÅëÀÌÁö¸¸ ÀÌ¿¡ ´ëÇÑ Áõ°Å´Â ¾àÇÕ´Ï´Ù. Serrated adenoma¿¡¼ dysplasia°¡ µ¿¹ÝµÈ ºñÀ²ÀÌ ³·Àº °Íµµ progressionÀÌ ºü¸£±â ¶§¹®À̶ó°í »ý°¢µË´Ï´Ù.
@ ÀÌÁØÇà comment: 2013³â 7¿ù 13ÀÏ EndoTODAY¿¡¼ ³íÀÇÇÑ ¹Ù ÀÖÁö¸¸, serrated adenoma¿¡ ´ëÇÑ ¿¬±¸´Â ÇöÀçÁøÇàÇüÀÔ´Ï´Ù. »ý°¢º¸´Ù ¸¹°í »ý°¢º¸´Ù Áß¿äÇÒ °Í °°½À´Ï´Ù.
3) Family history, HNPCC and polyposis syndrome: recognizing and timing of followup - Carol A. Burke
À¯Àü¼º ´ëÀå¾ÏÀº MYH associate polyposis ¸¸ »©°í ¸ðµÎ autosomal dominantÀÔ´Ï´Ù...... ¿©±â±îÁö µè°í Àá½Ã Á¹¾Ò½À´Ï´Ù. ¹Ì±¹ ÇÐȸ¿¡ Âü¼®ÇÑ´Ù´Â °ÍÀº Á߳뵿 Áß¿¡¼µµ Á߳뵿, °í¿ª Áß¿¡¼µµ °í¿ªÀÔ´Ï´Ù. ¸Ö¸® ¹Ì±¹±îÁö ¿Í¼ ¿½ÉÈ÷ ±×¸®°í Èûµé°Ô °øºÎÇÏ´Â ¿©·¯ ¼±»ý´ÔµéÀ» Á¸°æÇÕ´Ï´Ù. Àú´Â ¿©°£Çؼ± ¹Ì±¹ ÇÐȸ¿¡ ¾È ¿É´Ï´Ù. À̹ø¿¡ ¿Â °Íµµ 13³â¸¸ÀÔ´Ï´Ù.^^
4) Assessing when risk may outweigh the benefits: when to stop - Charles J. Kahi
CORI¿¡ µî·ÏµÈ ´ëÀå³»½Ã°æÀÇ 13%°¡ 75¼¼ ÀÌ»óÀÌ°í ´ëºÎºÐÀº polyp screeningÀÌ ¸ñÀûÀÔ´Ï´Ù. 80¼¼ À̻󿡼 ´ëÀå³»½Ã°æÀ» ÇßÀ» ¶§ »ýÁ¸±â°£Àº 0.13³â ¿¬ÀåµË´Ï´Ù (Lin. JAMA 2006).
°í·É¿¡¼´Â ´ëÀå³»½Ã°æÀÇ ÇÕº´ÁõÀÌ ÈçÇÕ´Ï´Ù (Warren. Ann Intern Med 2009) °í·ÉȯÀÚ´Â ¸Å¿ì ´Ù¾çÇÕ´Ï´Ù (The elderly are a heterogenous group). Chronological ageº¸´Ù´Â life expectancy¸¦ ºÁ¾ß ÇÕ´Ï´Ù. Lag effectµµ °í·ÁÇØ¾ß ÇÕ´Ï´Ù. CRC-specific mortality benefits does not appear until at least 5-7 years after screening (Shaukat NEJM 2013).
Life expectsncy°¡ 5-7³â ÀÌÇÏ¸é ´ëÀå¾Ï ¿¹¹æ¸ñÀûÀÇ ´ëÀå³»½Ã°æÀº Áß´ÜÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù.
@ ÀÌÁØÇà comment: ÃÖ±Ù Gastroenterology¿¡ "Lower endoscopy reduces colorectal cancer incidence in older individuals"¶ó´Â Á¦¸ñÀÇ ³í¹®À» ¹ßÇ¥ÇÑ ÀúÀÚÀÇ °ÀÇ¿´½À´Ï´Ù. µ¥ÀÌŸ´Â ¸¹ÀÌ Á¦½ÃÇߴµ¥ °á·ÐÀ» À̲ô´Â ¹æ½ÄÀº smartÇÏÁö ¸øÇß½À´Ï´Ù. Powerpoint ÀÚ·áµµ ¾û¸ÁÀ̾ú½À´Ï´Ù. ±ú¾Ë°°Àº ÅؽºÆ® ÀÚ·á¿©¼ ´«¿¡ µé¾î¿ÀÁö ¾Ê¾Ò½À´Ï´Ù. °ü½ÉÀÖ´Â ÁÖÁ¦¿´Áö¸¸ °ÀÇ´Â ½Ç¸Á½º·¯¿ü½À´Ï´Ù. ¿©ÇÏÆ° °á·Ð(life expectsncy°¡ 5-7³â ÀÌÇÏ¸é ´ëÀå¾Ï ¿¹¹æ¸ñÀûÀÇ ´ëÀå³»½Ã°æÀº Áß´ÜÇÏ´Â °ÍÀÌ ÁÁ´Ù)Àº Ÿ´çÇÏ´Ù°í ´À²¼½À´Ï´Ù.
2014. 5. 6. È¿äÀÏ SSAT/SAGES ½ÉÆ÷Áö¾ö
Âü¼®Çϱ⠾î·Á¿î ¼¼¼Ç Áß ¿Ü°úÀÇ»çµéÀÌ ÁÖµµÇÏ´Â Èï¹Ì·Î¿î ½Ã°£ÀÌ ÀÖ¾î ¼Ò°³ÇÕ´Ï´Ù. 2014³â 5¿ù 6ÀÏ Á¤¿À S504BCD, MCP¿¡¼ ¿¸®´Â SSAT/SAGES ½ÉÆ÷Áö¾öÀε¥ Á¦¸ñÀÌ Èï¹Ì·Ó½À´Ï´Ù. Quality indicators: defining it before someone else does it for us!
±×·¸½À´Ï´Ù. ½º½º·Î Áú°ü¸®¸¦ ÇÏÁö ¾ÊÀ¸¸é, ¿ì¸®°¡ Àß ÇÏ°í ÀÖ´Ù´Â °ÍÀ», ´õ ÀßÇϱâ À§Çؼ ¿ì¸® ½º½º·Î ³ë·ÂÇÏ°í ÀÖ´Ù´Â °ÍÀ», ¸»ÀÌ ¾Æ´Ï¶ó ½Ã½ºÅÛ°ú µ¥ÀÌŸ·Î Áõ¸íÇØ¾ß ÇÕ´Ï´Ù. ±×·¸Áö ¾ÊÀ¸¸é ´©±º°¡ ´Ù¸¥ »ç¶÷ÀÌ ´ë½ÅÇÒ °ÍÀÔ´Ï´Ù. ÁúÁöÇ¥¶ó´Â °ÍÀÌ ´Ù¼Ò ±ÍÂú°í Áö±Ý ´çÀå ÇÊ¿äÇÒ °Í °°Áö ¾Ê´Ù´Â ´À½¼ÇÑ Çö½ÇÀνĿ¡ ¾ÈÁÖÇÏ¸é °ð ¾²³ª¹Ì°¡ ´ÚĨ´Ï´Ù. Someone else°¡ Çϱâ Àü¿¡ ¿ì¸® ½º½º·Î ÁúÁöÇ¥¸¦ °³¹ßÇÏ°í À̸¦ ÀÌ¿ëÇÑ ÁúÇâ»ó È°µ¿À» ÇØ¾ß ÇÕ´Ï´Ù.
Quality indicator: defining it before someone else does it for us! ÀÌ Á¦¸ñ¿¡ ±¦È÷ ´À³¦Ç¥°¡ ºÙÀº °ÍÀÌ ¾Æ´Õ´Ï´Ù. Áö±Ý ´çÀå ÁúÁöÇ¥ °³¹ß¿¡ ³ª¼³ ¶§ÀÔ´Ï´Ù. ¿ì¸®ÀÇ practice¸¦ ¿ì¸® ½º½º·Î Æò°¡ÇÏ°í ÀÚÁ¤È°µ¿¿¡ ³ª¼Áö ¾ÊÀ¸¸é ¿ÜºÎ ¾Ð·Â°ú ±ÔÁ¦´Â ºÒº¸µí »·ÇÕ´Ï´Ù. Áö±Ý ½ÃÀÛÇսôÙ.
2014. 5. 7. 8AM. Maximizing colonoscopy quality
1) Large and sessile serrated lesions - maximizing detection and resection - Douglas Rex
10³â Àü¿¡´Â controlled study°¡ ¾ø¾ú´Âµ¥ ÀÌÁ¦´Â ¸¹Àº controlled study°¡ ÀÖ¾î¼ polypectomy°¡ science°¡ µÇ¾ú½À´Ï´Ù. Sessile serrated adenoma¿¡ ´ëÇÏ¿© contrast agent¸¦ injectÇÏ°í piecemeal resectionÇÏ¸é ±¹¼ÒÀç¹ßÀ» ¸·À» ¼ö ÀÖ½À´Ï´Ù.
@ ÀÌÁØÇà comment: ESD¸¦ ¸¹ÀÌÇÏ´Â ¿ì¸®ÀÇ ´«À¸·Î º¸¸é ´Ù¼Ò ½Ç¸Á½º·´Áö¸¸, flat adenoma¿¡ ´ëÇÑ multiple piecemeal injection Á¤µµµµ ¹Ì±¹¿¡¼´Â something new·Î °£ÁֵǴ ºÐÀ§±âÀÔ´Ï´Ù.
2) Improving ADRs and beyond - What quality indicators are important and how to improve them? - Philip Schoenfeld
- Adenoma detection rate (ADR) >25% (³²ÀÚ¿¡¼´Â 30%, ¿©ÀÚ´Â 20%). ADRÀ» ³ôÀ̱â À§Çؼ (1) withdrawal timeÀ» ´Ã¸®°í, (2) ÀåÁ¤°áÀ» Çâ»ó½ÃÅ°°í, (3) cecum¿¡¼ retroflectionÀ» ÇÏ´Â °ÍÀÌ ÃßõµË´Ï´Ù.
- Documented appropriate indication for colonoscopy > 80%. There is no clear indication for the early repeated examination in 23.5%.
- Adequate bowel preparation in outpatient setting > 85%. SplittingÀÌ ÁÁ½À´Ï´Ù.
- Cecal intubation rate with photodocumentation > 95%
- Documented appropriate recommendation for next colonoscopy > 90%. Hyperplastic polypÀ» Á¦°ÅÇÑ ÈÄ 5³â À̳»¿¡ Àç°ËÇÏ´Â °Í±îÁö ¹®Á¦¸¦ »ï°í ÀÖ½À´Ï´Ù. ¿ì¸®¿Í ´Þ¶óµµ ³Ê¹« ´Ù¸£³×¿ä.
- Average withdrawal time > 6 minutes. Withdrawal time¿¡ ´ëÇؼ´Â 6ºÐÀ̶ó´Â ¼ýÀÚ°¡ misquotedµÇ°í ÀÖ½À´Ï´Ù. Every single colonoscopy°¡ Ç×»ó 6ºÐ ÀÌ»óÀÌ µÇ¾î¾ß ÇÑ´Ù´Â ¶æÀº ¾Æ´Õ´Ï´Ù. ÀåÁ¤°áÀÌ ÁÁ°í °üÂûÀÌ ½¬¿î °Ë»ç´Â 6ºÐº¸´Ù ª°Ô ³¡³¯ ¼ö ÀÖ½À´Ï´Ù.
- Perforation < 1/1000
- Postpolypectomy bleeding < 1%
@ ÀÌÁØÇà comment: Rex ¹Ú»ç¿Í Lieberman ¹Ú»ç¿Í ÇÔ²² °¿¬ÇÒ ¼ö ÀÖ¾î¼ ¿µ±¤À̶ó´Â ¸»·Î ½ÃÀÛÇß½À´Ï´Ù. »ç½Ç À̹ø DDW ±â°£ µ¿¾È ÀÌ µÎºÐÀº ³Ê¹« ¸¹ÀÌ µîÀåÇß½À´Ï´Ù. ¶Ç ³ª¿À°í, ¶Ç ³ª¿À°í, ¶Ç ³ª¿À°í... ÁÂÀåµµ ÇÏ°í ¿¬ÀÚµµ ÇÏ°í... ÇÑ ÇÐȸ¿¡¼´Â Çѹø¸¸ ³ª¿Â´Ù´Â ¾Ï¹¬ÀûÀÎ ·êÀ» °¡Áö°í ÀÖ´Â ¿ì¸®³ª¶ó¿Í´Â »ç¹µ ´Ù¸¥ ºÐÀ§±âÀÔ´Ï´Ù. ¿ª½Ã °¡Àå Áß¿äÇÑ ÁöÇ¥´Â ADRÀÔ´Ï´Ù. Indication ¾øÀÌ Áö³ªÄ¡°Ô °Ë»ç¸¦ ÀÚÁÖ ÇÏ´Â °ÍÀ» ÁöÇ¥·Î ¸¸µé¾ú´Ù´Â Á¡ÀÌ Æ¯ÀÌÇÏ°í Áß¿äÇÒ °Í °°½À´Ï´Ù. Àû¾îµµ ¹Ì±¹ ¹®È¿¡¼´Â. ¿ì¸®³ª¶ó¿¡ Àû¿ëÇϱ⿡´Â ¾ÆÁ÷ ½Ã±â»óÁ¶ÀÔ´Ï´Ù. ¸¶Áö¸·¿¡ Àû¿ëÇØ¾ß ÇÒ ÁöÇ¥°¡ ¾Æ´Ñ°¡ »ý°¢ÇÕ´Ï´Ù. ´Ù¸¥ ÁúÁöÇ¥°¡ ÁÁ¾ÆÁö°í ³ ´ÙÀ½¿¡ ÀûÀÀÁõÀ» °ü¸®ÇÏ´Â °ÍÀÌ ¼ø¼ÀÏ °Í °°½À´Ï´Ù. ¿¬ÀÚÀÇ °ÀÇ Áß¿¡ ³ª¿Ô´ø ¸» Áß¿¡¼ ÀλóÀûÀÎ °Í ¸î °³¸¦ ¸ð¾Æº¸¾Ò½À´Ï´Ù.
3) Surveillance intervals: getting them right - David Lieberman
Fee for service »óȲ¿¡¼ °æÁ¦ÀûÀ¸·Î´Â more is goodÀÏ ¼ö ¹Û¿¡ ¾øÀ¸¹Ç·Î colonoscopy overuse°¡ ¹®Á¦¶ó°í ÇÕ´Ï´Ù. "We have to think how we positon ourselves."¶ó°í ¸»ÇÏ°í ÀÖ½À´Ï´Ù. ¹«Ã´ ÀλóÀûÀ̾ú½À´Ï´Ù.
Áß°£¾ÏÀº 0.3 - 0.9% in 3-5 yearsÁ¤µµ¶ó°í Çϴµ¥ cancer registry ÀÚ·á¿¡ ÀÇÇϸé À̺¸´Ù ´Ù¼Ò ³ô´Ù°í ÇÕ´Ï´Ù. µî·ÏÀÚ·á¿¡ ÀÇÇÏ¸é ´ëÀå¾Ï ȯÀÚÀÇ 2-9%´Â 3³â À̳»¿¡ ´ëÀå³»½Ã°æÀ» ¹ÞÀº ÀûÀÌ ÀÖ´Ù°í ³ª¿É´Ï´Ù. Áß°£¾ÏÀÇ ÀÌÀ¯´Â (1) serrate pathwayÀÎ °ÍÀÌ ¸¹¾Æ¼ ¹ß°ßÀÌ ¾î·Á¿ò, (2) incomplete resection, (3) missed lesion (1cm ÀÌ»óÀÇ ¿ëÁ¾ÀÇ 17%°¡ missedµÈ´Ù´Â ¿¬±¸µµ ÀÖ´Ù°í ÇÕ´Ï´Ù) ÀÌ ¾ð±ÞµÇ¾ú½À´Ï´Ù.
"We can make the quality better. Perhaps, the benefit comes from quality primary examination."¶ó´Â ¸»·Î ¸Î°í ÀÖ½À´Ï´Ù.
4) ÀÌÁØÇà ÃÑÆò
Âü ¸¹Àº °ÍÀ» µÇµ¹¾Æº¸°Ô ÇÏ´Â ½Ã°£À̾ú½À´Ï´Ù. ´ç¿¬ÇÑ °ÍÀ» ´ç¿¬ÇÏ°Ô »ý°¢ÇÏ´Â °Í, Áß¿äÇÑ °ÍÀ» Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °ÍÀÌ ±âº»ÀÔ´Ï´Ù. ±âº»À» Àß ÁöÄÑ¾ß ¾ÈÀüÇÑ °ÍÀ̱¸¿ä.
1. Çѹø ÇÏ´õ¶óµµ Àß ÇÏ´Â °ÍÀÌ Áß¿äÇÏÁö ´ë° ¿©·¯¹ø °Ë»çÇϸé quality°¡ ³·Àº °ÍÀ¸·Î °£Áֵ˴ϴÙ. ³Ê¹« ´ç¿¬ÇÑ À̾߱âÁö¸¸ ¿ì¸®´Â °£È¤ À̸¦ ÀØ°í Áö³»´Â °ÍÀº ¾Æ´Ñ°¡ »ý°¢µË´Ï´Ù.
2. ¹Ì±¹¿¡¼´Â ÀÏÁ¤ ºÎºÐ Áß°£¾ÏÀÌ ÀÖ´Ù´Â °ÍÀ» ÀÚ·á·Î ¸¸µé¾î Àǻ縦 º¸È£ÇÏ°í ÀÖ½À´Ï´Ù. ¹°·Ð Áß°£¾ÏÀ» ÁÙÀ̱â À§ÇÏ¿© ADR¸¦ ³ôÀÌ´Â µî ÁúÇâ»óµµ ÇÔ²² °Á¶µÇ°í ÀÖÁö¸¸... ÀڷḦ ¸ðÀ¸´Â °ÍÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿ì¸®´Â Àϸ¸ ÇÏ°í ÀÚ·á ¸ðÀ¸´Â °ÍÀº ³Ê¹« ¼ÒȦÈ÷ ÇÏ°í ÀÖ´Â °ÍÀº ¾Æ´Ò±î¿ä?
3. Measurement is now new normalÀ̶ó´Â °ÍÀ» ¿ì¸®µµ ¹Þ¾Æµé¿©¾ß ÇÒ °Í °°½À´Ï´Ù. ¹®Á¦´Â ³²ÀÌ ¸¸µé¾îÁÖ±â Àü¿¡ ¿ì¸® ½º½º·Î ¸ÕÀú ¸¸µé¾î¾ß ÇÑ´Ù´Â °ÍÀÌÁö¿ä. ±¹°¡±â°ü¿¡¼ ÀڷḦ ¸¸µé±â Àü¿¡ ¿ì¸® º´¿ø¿¡¼, ¿ì¸® ÇÐȸ¿¡¼ ¸ÕÀú ¸¸µé¾î¾ß ÇÕ´Ï´Ù. ±×·¡¾ß¸¸ ºÒÇÊ¿äÇÑ È¥¼±À» ÇÇÇÒ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù.
4. Adenoma detection rate¸¦ ³ôÀ̱â À§ÇÏ¿© ÀÇ»çµé¸¸ Àß Ç϶ó°í ÇÏÁö ¸»°í ȯÀÚ ±³À°À» ÅëÇؼµµ °³¼±ÇÒ ¼ö ÀÖ´Ù´Â floorÀÇ ÀÇ°ßÀÌ ÀÖ¾ú½À´Ï´Ù. ÀεµÂÊ ¼±»ý´Ô °°¾Ò½À´Ï´Ù.
5. Adenoma detection rate¸¦ ³ôÀ̱â À§ÇÏ¿© chromoendoscopy³ª ´Ù¸¥ ±â¹ýµéÀ» »ç¿ëÇÏ´Â °Íµµ °ÀÇ¿¡ Æ÷ÇԵǸé ÁÁ°Ú´Ù´Â floorÀÇ ÀÇ°ßÀÌ ÀÖ¾ú½À´Ï´Ù. È«Äá ¼±»ý´Ô °°¾Ò½À´Ï´Ù.
6. ADRÀ¸·Î´Â ºÎÁ·ÇÏ°í serrated adenoma detection rateµîÀÌ ´õ Áß¿äÇÏ´Ù´Â floor¿¡¼ÀÇ comment°¡ ÀÖ¾ú½À´Ï´Ù. Schenfeld ¹Ú»ç´Â ÇöÀçÀÇ ADRÀÇ Á¤ÀÇ°¡ ³Ê¹« ´Ü¼øÇÏ´Ù°í ´äÇß°í Rex ¹Ú»ç´Â pathologistÀÇ ¿ë¾î°¡ ÅëÀϵÇÁö ¾Ê¾ÒÀ½À» ÁöÀûÇß½À´Ï´Ù.
2014. 5. 7. 10AM. H. pylori controversies in 2014
ÁÂÀåÀÎ Jean Marie HoughtonÀº ù °ÀÇ Àü »çÁøÀ» ÂïÁö ¸»¶ó°í ¸»Çß½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ù °»çÀÎ Blaser ¹Ú»çÀÇ °ÀÇ ½½¶óÀ̵带 »çÁø Âï´Â »ç¶÷µéÀÌ ÀÖ¾ú½À´Ï´Ù. ´ëºÎºÐ µ¿³²¾Æ½Ã¾Æ ȤÀº ³²¾Æ½Ã¾Æ °è¿ÀÇ ¼±»ý´ÔµéÀ̾ú½À´Ï´Ù. ù °ÀÇ°¡ ³¡³ ÈÄ ÁÂÀåÀÌ ´Ù½Ã »çÁøÂïÁö ¸»¶ó°í Â¥Áõ½º·± Ç¥Á¤À¸·Î ¾î³ª¿î½º¸¦ Çß½À´Ï´Ù.
¹®µæ ÀÌ·± »ý°¢À» Çß½À´Ï´Ù. »çÁøÀ» ÂïÀ¸¸é Á¤¸» ¾ÈµÇ´Â °ÍÀϱî¿ä? »ç½Ç flash¸¦ ¾²Áö ¾ÊÀ¸´Ï °ÀÇ¿¡ ¹æÇصǴ »óȲµµ ¾Æ´Ï¾ú½À´Ï´Ù. ûÁß ÀÔÀå¿¡¼µµ ¾à°£ ´«¿¡ °Å½½¸®±ä ÇÏÁö¸¸ °ÀÇ ³»¿ëÀ» µû¶ó°¡´Âµ¥ ÀüÇô ¹®Á¦µÇÁö ¾Ê¾Ò½À´Ï´Ù. ±×·±µ¥µµ ¿Ö »çÁøÀ» ÂïÁö ¸»¾Æ¾ß ÇÏ´Â °ÍÀϱî¿ä? °»çÀÇ ÀúÀÛ±Ç ¶§¹®À̶ó°í ÇÕ´Ï´Ù. ???
Àú´Â ÀúÀÛ±Ç µÚ¿¡ ¼û°ÜÁø À½¸ð¸¦ ´À³§´Ï´Ù. »ç½Ç ÀúÀÛ±ÇÀ̶ó´Â °³³äÀÌ »ý±ä °ÍÀº ¼ö½Ê³â ¹Ì¸¸ÀÔ´Ï´Ù. ¹ÙÇÏ´Â ¸Å¿ì âÀÇÀûÀÎ ÀÛ°î°¡¿´Áö¸¸ µ¿½Ã´ë ¿©·¯ ÀÛ°î°¡ÀÇ À½¾ÇÀ» ¾öû º£²¼½À´Ï´Ù. ¸ðÂ¥¸£Æ®µµ ¸¶Âù°¡Áö°í, º£Å亥µµ ¸¶Âù°¡ÁöÀÔ´Ï´Ù. ÁÁÀº À½¾ÇÀ» µè°í ÇÔ²² Áñ°Å¿öÇÏ°í ÇÔ²² Á¤½ÅÀÌ °í¾çµÇ¸é ±×¸¸À̾ú½À´Ï´Ù. ´©°¡ ±× À½¾ÇÀ» âÁ¶Çß´ÂÁö µûÀ§´Â Áß¿äÇÏÁö ¾Ê¾Ò½À´Ï´Ù. ¿äÁò ¹Ì¼ú°ü¿¡¼ »çÁø ÃÔ¿µÀº ´ç¿¬ÇÑ ÀÏÀÔ´Ï´Ù. ´ëºÎºÐ ÇÚµåÆùÀ¸·Î flash ¾øÀÌ Âï±â ¶§¹®¿¡ ¸£³ë¿Í¸£ ÀÛÇ°À̵ç ÇÇÄ«¼Ò ÀÛÇ°ÀÌµç ¾ó¸¶µçÁö Âï¾îµµ ÁÁ½À´Ï´Ù. ÀúÀÛ±ÇÀº µ·°ú °ü·ÃµË´Ï´Ù. ³²ÀÌ º£³¢¸é ³»°¡ µ·À» ¹úÁö ¸øÇϹǷΠº£³¢Áö ¸øÇÏ°Ô ÇÏ´Â °Í ¾Æ´Ò±î¿ä? »ç½Ç ÀúÀÛ±ÇÀº ¼±Áø±¹ÀÇ ±âµæ±ÇÀ» À¯Áö º¸°Çϱâ À§ÇÑ ÀåÄ¡ÀÎ ¼ÀÀÔ´Ï´Ù.
DDW (»ç½Ç ÀÌ À̸§µµ ¸¾¿¡ µéÁö ¾Ê½À´Ï´Ù. American DDW°¡ ¿ÇÁö ¾ÊÀº°¡¿ä?)¿¡ ã¾Æ¿Â °¡³ÇÑ ³ª¶óÀÇ ÀÇ»çµéÀº Çϳª¶óµµ ´õ ¹è¿ö¼ Àڱ⠱¹¹ÎÀÇ °Ç°Çâ»ó¿¡ Èû¾²°íÀÚ ÇßÀ» °ÍÀÔ´Ï´Ù. »çÁø Âï¾î¼ ¹«½¼ Å« µ·À» ¹ú·Á°í ÇÑ °ÍÀº ¾Æ´Ò °ÍÀÔ´Ï´Ù. DDW¿¡ ¿ÀÁö ¸øÇÑ µ¿·áµé¿¡°Ô ÀڱⰡ ¹è¿î °ÍÀ» Àü´ÞÇϱâ À§ÇÔÀÏ ¼öµµ ÀÖ½À´Ï´Ù. DDW¿¡¼ ºñ½Î°Ô ÆÄ´Â °ÀÇ µ¿¿µ»ó DVD¸¦ »ì µ·ÀÌ ¾ø¾úÀ» ¼öµµ ÀÖ½À´Ï´Ù. »çÁ¤ÀÌ ÀÌ·²Áøµ¥ »çÁø Âï´Â »ç¶÷À» ¹«½¼ °ÅÁö ȤÀº µµµÏó·³ Ãë±ÞÇÏ¸é¼ ¾ð¼ºÀ» ³ôÀÏ ÇÊ¿ä°¡ ÀÖ¾úÀ»±î¿ä? ³Ê¹«ÇÏ´Ù´Â »ý°¢ÀÌ µé¾ú½À´Ï´Ù.
±ä ¾È¸ñÀ¸·Î »ý°¢Çغ¾½Ã´Ù. °ÀÇ¿¡ »ç¿ëµÈ ÀÚ·á´Â ¼·Î¼·Î »çÁøÂï°í º£²¸¼ Àηù °Ç° Çâ»ó¿¡ ³Î¸® »ç¿ëÇÏ´Â °ÍÀÌ ´õ ÁÁÀº ÀÏ ¾Æ´Ñ°¡¿ä? ÀÇ»ç´Â ȯÀÚ¶§¹®¿¡ Á¸ÀçÇÏ´Â °Í ¾Æ´Ñ°¡¿ä? ÀÇÇÐ ¿¬±¸µµ °á±¹ ȯÀÚÄ¡·á¸¦ Àß ÇÏ·Á´Â ÀÏ ¾Æ´Ñ°¡¿ä? ȯÀÚ Ä¡·á¿¡ µµ¿òµÈ´Ù¸é °ÀÇ ½½¶óÀÌµå °°Àº °ÍÀº ¾ó¸¶µçÁö »çÁøÂïµµ·Ï ÇØ¾ß ÇÏ´Â °Í ¾Æ´Ò±î¿ä? ³» ¹ßÇ¥³»¿ëÀ» º¸´Ù ¸¹Àº »ç¶÷ÀÌ ¾Ë°ÔµÇ°í ±× °á°ú ÇѸíÀÌ¶óµµ ´õ °Ç°ÇØÁø´Ù¸é ±×°Ô º¸¶÷ÀÖ´Â ÀÏ ¾Æ´Ò±î¿ä?
ÀÇ·á¿¡¼ ¿ÏÀüÈ÷ µ· ³¿»õ¸¦ Áö¿ï ¼ö´Â ¾øÀ» °ÍÀÔ´Ï´Ù. ÀÇ·áµµ Å« »ê¾÷À̴ϱî¿ä. ±×·¯³ª Àû¾îµµ ÀÇÇÐ ¿¬±¸¿Í Çмú ±³·ù¿¡¼´Â µ·³¿»õ°¡ ¸¹ÀÌ ³ª¸é ¾È µÈ´Ù°í »ý°¢ÇÕ´Ï´Ù.
ȯÀÚµéÀÌ º¸°í ÀÖ½À´Ï´Ù. ³ÊÈñ ÀÇ»çµé¿¡°Ô ÁÁÀº ÀÏ ÇÏÁö ¸»°í ¿ì¸® ȯÀڵ鿡°Ô ÁÁÀº ÀÏ Ç϶ó°í ¸í·ÉÇÏ°í ÀÖ½À´Ï´Ù. ÀÇ»ç´Â °á±¹ healthcare providerÀÔ´Ï´Ù. ȯÀÚ¿¡°Ô service¸¦ Á¦°øÇÏ´Â »ç¶÷ÀÔ´Ï´Ù. ȯÀÚ°¡ ÀÇ»çÀÇ ÁÖÀÎÀÔ´Ï´Ù. ÁÖÀο¡°Ô ÁÁÀº ÀÏÀ» ÇØ¾ß ÇÏ´Â °Í ¾Æ´Ò±î¿ä?
/»ç/Áø/ÃÔ/¿µ/À»/Çã/ÇÏ/¶ó/!/
1) The case for not treating every patient with H. pylory infection. (by Martin J. Blaser)
Blaser ¹Ú»ç´Â Helicobacter´Â gastric microbiome ÀÇ dominant member¶ó´Â ¸»·Î °ÀǸ¦ ½ÃÀÛÇß½À´Ï´Ù. À§¿¡´Â ´Ù¸¥ ±ÕÀº ¾ø°í Ç︮ÄÚ¹ÚÅ͸¸ ÀÖ´Ù´Â °³³äÀº ÀÌ¹Ì ¿¾³¯À̾߱Ⱑ µÇ¾ú½À´Ï´Ù.
Helocobacter´Â õ½Ä°ú ¿ª»ó°ü°ü°è°¡ ÀÖ½À´Ï´Ù. Helicobacter°¡ ÁÙ¸é¼ ¹Ù·¿½Äµµ¿Í ½Äµµ¼±¾ÏÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. Helicobacter ¾ç¼º ¿ø¼þÀÌ¿¡¼ °áÇÙÀÇ reactivationÀÌ Àû´Ù´Â ¿¬±¸µµ ÀÖ¾ú½À´Ï´Ù. NHANES III¿¬±¸¿¡ ÀÇÇϸé HelicobacterÀÇ mortality¿¡ ´ëÇÑ OR°¡ 1.0 À̾ú½À´Ï´Ù (2013 Gut). À§¾Ï¸¸ OR°¡ 40À̾ú½À´Ï´Ù. Blaser ¹Ú»ç´Â Helicobacter´Â mortality¿¡ ´ëÇÏ¿© complex roleÀ» °¡Áö°í Àִµ¥ netÀ¸·Î ±× ¿µÇâÀº 1.0À̶ó°í ¸»ÇÏ°í ÀÖ½À´Ï´Ù.
°ÀÇ¿¡ ¾ð±ÞµÈ ¿©·¯ ¿¬±¸ÀÚ¿¡°Ô °¨»çÇÏ´Ù´Â Àλ縦 ÇÏ¸é¼ ¸í´ÜÀ» º¸¿©ÁÖ¾ú´Âµ¥ ¿¬¼¼´ëÇб³ ÀÌ¿ëÂù ¼±»ý´ÔÀÇ À̸§ÀÌ º¸¿´½À´Ï´Ù. Á¤·ÄÀûÀ¸·Î ¸¹Àº ¿¬±¸¸¦ ÇϽô ÀÌ¿ëÂù ±³¼ö´ÔÀ» Á¸°æÇÕ´Ï´Ù.
2) Helicobacter resistance (by Megraud)
¾ÆÁ÷ Á¤´äÀÌ ¾ø¾î º¸ÀÔ´Ï´Ù.
3) Why the only good H. pylori is a dead H. pylori (by David Y. Graham)
½Ê³â° °°Àº Á¦¸ñÀ¸·Î °ÀǸ¦ ÇÏ´Â °Íµµ ÀçÁÖ¶ó°í º¾´Ï´Ù. ³»¿ëÀº Á¶±Ý¾¿ ´Þ¶óÁø´Ù°í Çϳ׿ä. »õ·Î ¾Ë°Ô µÈ »ç½Ç. 1910³â¿¡´Â ¼¼°è¿¡¼ À§¾ÏÀÌ °¡Àå ¸¹Àº ³ª¶ó°¡ ½ºÀ§½º¿´½À´Ï´Ù.
º£¸® ¸¶¼£ ¹Ú»ç°¡ Ç︮ÄÚ¹ÚÅÍÀÇ beneficial effect¸¦ À§ÇÏ¿© Á×Àº Ç︮ÄÚ¹ÚÅÍÀÇ extract¸¦ ¾²¸é ¾î¶³±î Áú¹®ÇÏ¿´°í, ±×¶óÇÔ ¹Ú»ç´Â Ç︮ÄÚ¹ÚÅÍ°¡ beneficial effect°¡ ÀÖ´Ù´Â °ÍÀº myth¶ó°í ´äÇÏ°í ÀÖ±º¿ä. µ¿¹®¼´ä.
4) PPI therapy in H. pylori positive patients should we be concerned? (by Nimish B. Vakil)
¸¹Àº for µ¥ÀÌƼ¿Í against µ¥ÀÌŸ°¡ Á¦½ÃµÇ¾ú½À´Ï´Ù. ÀúÀÚ´Â Á¦±ÕÄ¡·á¸¦ ÇÏ´Â ÂÊ¿¡ ¼ÕÀ» µé¾îÁÖ¾ú½À´Ï´Ù. ´Ü healthcare policy·Î recommendÇÏ·Á¸é cost effectiveness data°¡ ÇÊ¿äÇÏ´Ù°í ¾ð±ÞÇÏ°í ÀÖ½À´Ï´Ù.
1) ¹Ì±¹ÀÇ ÁÖµµ±ÇÀÌ Á¡Á¡ ¾àÇØÁö´Â ´À³¦ÀÔ´Ï´Ù. ³»½Ã°æ ºÐ¾ß¿¡¼´Â ¶Ñ·ÇÇÑ °ÀÚ°¡ ¾ø´Â ½Ã´ë°¡ µÇ¾ú½À´Ï´Ù. ¹Ì±¹¼Òȱ⳻½Ã°æÇÐȸ¿¡¼´Â ÀϺ», Çѱ¹, Áß±¹, ³²¹Ì µî ¿©·¯ ³ª¶ó¿Í °øµ¿½ÉÆ÷Áö¾öÀ» °³ÃÖÇÏ¿© ¸í¸ÆÀ» À¯ÁöÇÏ´Â ¸ð½ÀÀÌ »ì¦ º¸¿´½À´Ï´Ù. ¹Ì±¹À» Á¦¿ÜÇÑ ¿©·¯ ³ª¶ó¿¡¼´Â ½Å±â¼ú°ú µµÀüÀûÀÎ »ç¼úÀ» ÅëÇØ ¹Ì·¡¸¦ ¿¾î°¡°í ÀÖ´Â ¹Ý¸é, ¹Ì±¹Àº ±¹³»¹®Á¦¿¡ Ä¡ÁßÇÏ°í ÀÖ´Â ´À³¦À̾ú½À´Ï´Ù. ¼¼°èÀû ¸®´õ½ÊÀº ½ÇÁ¾.
2) Ç︮ÄÚ¹ÚÅÍ ºÐ¾ß´Â ÃÖ±Ù 5³â ȤÀº 10³â Á¤µµ ´äº¸»óÅ°¡ °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ¿¬±¸ÀÚ´Â ´«¿¡ ¶çÁö ¾Ê°í °ú°ÅÀÇ ´ë°¡µéÀÌ ¾ÆÁ÷µµ podiumÀ» Àå¾ÇÇÏ°í ÀÖ¾ú½À´Ï´Ù.
3) Microbiata°¡ ÇÙ½É À̽´¿´½À´Ï´Ù. ¶È¶ÈÇÑ ½ÅÁø ¿¬±¸ÀÚµéÀÌ ¸ô·ÁÀÖ½À´Ï´Ù. ±×µ¿¾È ÇØ°áÀÌ ¾î·Á¿ü´ø IBS, C. difficile infection, Celiac sprue µîÀÌ ÇØ°áµÉÁöµµ ¸ð¸¥´Ù´Â »õ·Î¿î Èñ¸ÁÀÌ º¸ÀÔ´Ï´Ù. ÇÏÁö¸¸ »óºÎÀ§Àå°ü ¿µ¿ª¿¡´Â Å« ¿ªÇÒÀÌ ÀÖ´Â °Í °°Áö ¾Ê½À´Ï´Ù. Àû¾îµµ ¾ÆÁ÷±îÁö´Â.
4) °³ÀÎÀûÀ¸·Î´Â 13³â¸¸ÀÇ DDW ¹æ¹®ÀÎÁö¶ó ¾î¸®µÕÀýÇß½À´Ï´Ù. ±×µ¿¾È ¿ÀÁö ¾Ê¾Ò´ø °ÍÀÌ Á¶±Ýµµ ÈÄȸµÇÁö ¾Ê¾Ò½À´Ï´Ù. 5³â¿¡ Çѹø ¿Íµµ µÇ°Ú´Ù ½Í¾ú½À´Ï´Ù. ½ÃÄ«°í ¹Ì¼ú°üÀº ¶Ç °¡º¸°í ½Í½À´Ï´Ù. ¾à°£ ºÎ·´±âµµ Çß½À´Ï´Ù. Çѱ¹ ûÀÚµµ ¸î Á¡ ÀÖ¾ú´Âµ¥ ÀϺ» ¹ÌÂêºñ½Ã ȸ»ç°¡ ±âºÎÇؼ ¸¸µé¾îÁø °ø°£ÀÎÁö¶ó È°¡ ³ª´õ±º¿ä. ¿ì¸®³ª¶ó Å« ȸ»çµéÀº µµ´ëü ¹»ÇÏ°í ÀÖ´Â °ÍÀÎÁö...
5) DDW¸¦ ãÀº Çѱ¹ ¼±»ý´ÔµéÀº ¼¼¿ùÈ£ Âü»ç ¿µÇâÀÎÁö ´Ù¼Ò Â÷ºÐÇÑ ºÐÀ§±â¸¦ À¯ÁöÇß½À´Ï´Ù. ´Ù¸¸ ÇÐȸÀå¿¡¼ ´ëºÎºÐÀÇ ½Ã°£À» º¸³»´Â ºÐÀÌ ¸¹Áö ¾ÊÀº °Í °°¾Æ ¾Æ½¬¿ü½À´Ï´Ù. DDW¿¡´Â °øºÎ°¡ ÁÖ ¸ñÀûÀÎ »ç¶÷µé¸¸ º¸³»¾ß ÇÒ °Í °°½À´Ï´Ù. ¿©ÇàÀÌ ÁÖ¸ñÀûÀÎ »ç¶÷Àº ¿ÀÁö ¸¶¼¼¿ä. ¹º°¡ ´ëÃ¥ÀÌ ÇÊ¿äÇÕ´Ï´Ù. 10³â Àü¿¡ ºñÇؼ ¸¹ÀÌ ÁÁ¾ÆÁ³´ÙÁö¸¸ ¾ÆÁ÷ ÃæºÐÄ¡ ¾Ê¾Æ º¸ÀÔ´Ï´Ù.